Last reviewed · How we verify
Cyclophosphamide, Epirubicin, Paclitaxel
Cyclophosphamide, Epirubicin, Paclitaxel is a Combination chemotherapy (alkylating agent, anthracycline, taxane) Small molecule drug developed by North Eastern German Society of Gynaecological Oncology. It is currently in Phase 3 development for Breast cancer (neoadjuvant and adjuvant treatment), Gynecological malignancies.
This combination chemotherapy regimen uses three cytotoxic agents to damage cancer cell DNA and disrupt cell division, commonly used in breast cancer treatment.
This combination chemotherapy regimen uses three cytotoxic agents to damage cancer cell DNA and disrupt cell division, commonly used in breast cancer treatment. Used for Breast cancer (neoadjuvant and adjuvant treatment), Gynecological malignancies.
At a glance
| Generic name | Cyclophosphamide, Epirubicin, Paclitaxel |
|---|---|
| Sponsor | North Eastern German Society of Gynaecological Oncology |
| Drug class | Combination chemotherapy (alkylating agent, anthracycline, taxane) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Cyclophosphamide is an alkylating agent that cross-links DNA strands; Epirubicin is a topoisomerase II inhibitor that intercalates into DNA and prevents replication; Paclitaxel is a microtubule stabilizer that prevents mitotic spindle disassembly. Together, these agents attack cancer cells through multiple mechanisms to maximize cytotoxic effect.
Approved indications
- Breast cancer (neoadjuvant and adjuvant treatment)
- Gynecological malignancies
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Alopecia
- Peripheral neuropathy
- Cardiotoxicity
- Mucositis
Key clinical trials
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- A Single-Arm, Single-Center, Phase II Clinical Study of Camrelizumab Combined With Radiochemotherapy as Neoadjuvant Therapy for Early-Stage Triple-Negative Breast Cancer (NA)
- LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer (PHASE2)
- Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) (PHASE2)
- QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer (PHASE2)
- Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer (PHASE2)
- A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003) (PHASE2)
- Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant Chemotherapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cyclophosphamide, Epirubicin, Paclitaxel CI brief — competitive landscape report
- Cyclophosphamide, Epirubicin, Paclitaxel updates RSS · CI watch RSS
- North Eastern German Society of Gynaecological Oncology portfolio CI
Frequently asked questions about Cyclophosphamide, Epirubicin, Paclitaxel
What is Cyclophosphamide, Epirubicin, Paclitaxel?
How does Cyclophosphamide, Epirubicin, Paclitaxel work?
What is Cyclophosphamide, Epirubicin, Paclitaxel used for?
Who makes Cyclophosphamide, Epirubicin, Paclitaxel?
What drug class is Cyclophosphamide, Epirubicin, Paclitaxel in?
What development phase is Cyclophosphamide, Epirubicin, Paclitaxel in?
What are the side effects of Cyclophosphamide, Epirubicin, Paclitaxel?
Related
- Drug class: All Combination chemotherapy (alkylating agent, anthracycline, taxane) drugs
- Manufacturer: North Eastern German Society of Gynaecological Oncology — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Breast cancer (neoadjuvant and adjuvant treatment)
- Indication: Drugs for Gynecological malignancies
- Compare: Cyclophosphamide, Epirubicin, Paclitaxel vs similar drugs
- Pricing: Cyclophosphamide, Epirubicin, Paclitaxel cost, discount & access